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Abstract: Cardiac hypertrophy is an adaptive and compensatory mechanism preserving cardiac output
during detrimental stimuli. Nevertheless, long-term stimuli incite chronic hypertrophy and may lead
to heart failure. In this review, we analyze the recent literature regarding the role of ERK (extracellular
signal-regulated kinase) activity in cardiac hypertrophy. ERK signaling produces beneficial effects
during the early phase of chronic pressure overload in response to G protein-coupled receptors
(GPCRs) and integrin stimulation. These functions comprise (i) adaptive concentric hypertrophy and
(ii) cell death prevention. On the other hand, ERK participates in maladaptive hypertrophy during
hypertension and chemotherapy-mediated cardiac side effects. Specific ERK-associated scaffold
proteins are implicated in either cardioprotective or detrimental hypertrophic functions. Interestingly,
ERK phosphorylated at threonine 188 and activated ERK5 (the big MAPK 1) are associated with
pathological forms of hypertrophy. Finally, we examine the connection between ERK activation and
hypertrophy in (i) transgenic mice overexpressing constitutively activated RTKs (receptor tyrosine
kinases), (ii) animal models with mutated sarcomeric proteins characteristic of inherited hypertrophic
cardiomyopathies (HCMs), and (iii) mice reproducing syndromic genetic RASopathies. Overall,
the scientific literature suggests that during cardiac hypertrophy, ERK could be a “good” player to be
stimulated or a “bad” actor to be mitigated, depending on the pathophysiological context.
Keywords: ERK pathway; adaptive and maladaptive hypertrophy; anthracycline-induced
cardiotoxicity; hypertrophic cardiomyopathy; RASopathies; target therapies
1. Introduction
The mitogen-activated protein kinase (MAPK) pathway (also known as the RAS-RAF-MEK-ERK
pathway) is a central signaling cascade activated by receptor tyrosine kinases (RTKs) upon binding
by extracellular mitogenic ligands [1,2]. RAS is a small GTP-binding protein that is activated by
tyrosine kinase receptors and transmits the signal from the cell membrane to the nucleus. At the
plasmamembrane, RAS activates the RAF kinase (MAPKKK), which in turn activates the MEK
kinase (MAPKK), which consecutively stimulates the ERK (extracellular signal-regulated kinase;
MAPK) through serial phosphorylation. The prototypical ERK 1/2 isoforms (here named ERK in its
singular noun) are responsive to stimulation to growth factors and have apparent redundant functions.
Once activated, ERK translocates to the nucleus and phosphorylates multiple substrates, including
transcription factors, such as CREB and Elk1. The activation and repression of nuclear targets result
in the induction of growth and proliferation and in the prevention of cell death [1]. Moreover, ERK
phosphorylates intracellular substrates in the cytoplasm, among which cytoskeletal and adherens
junction proteins as well as apoptotic and cell cycle regulators stand out. Since proliferation and cell
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growth are important processes for heart development, it is not surprising that ERK plays a central
role in cardiac physiology [3]. Importantly, the ERK molecules are implicated in several forms of
cardiac hypertrophy and progression to heart failure [3–8]. The role of ERK in the hypertrophic process
is, however, controversial and has not been fully understood [9]. ERK seems to be involved in the
induction of the adaptive hypertrophy, since transgenic mice expressing activated MEK1, the specific
activator of ERK, show concentric cardiac hypertrophy with enhanced contractile force [4]. Notably,
these mice did not show signs of pathological hypertrophy, such as fibrosis or sudden death. On the
other hand, the overexpression of activated MEK5, which specifically stimulates ERK5 (the big MAPK),
facilitates maladaptive, eccentric cardiac hypertrophy and leads to cardiomyopathy and sudden
death [10]. Not only the specificity, but also the intensity, duration, and localization of ERK signaling
may be directed towards adaptive or maladaptive hypertrophy. The balance of ERK signaling decides
its beneficial/detrimental role in the hypertrophic process.
In this review, we examine the more recent literature regarding the function of ERK pathway in
adaptive or maladaptive remodeling involved in cardiac hypertrophy. We focus on the actions mediated
by ERK in cardiomyocytes, which represent the major cell type of the cardiac organ. Although ERK
signaling has an impact also on fibroblasts and endothelial cells, such discussion is beyond the scope of
this review. Moreover, we address the involvement of ERK signaling in hereditary cardiomyopathies
and RASopathies, in which hypertrophy is a typical pathological feature. Finally, we discuss recent
scientific results addressing ERK signaling as a therapeutic target to manage cardiac hypertrophy.
2. Overview of Cardiac Hypertrophy
The heart reacts to a large number of physiological and pathological stimuli through cardiac
hypertrophy [11]. Since the cardiac muscle cells are terminally differentiated and have a limited ability
to proliferate, the heart modifies its volume and muscle mass by hypertrophic remodeling to increase
the contractile force and workload. During this dynamic response, the cardiomyocytes increase in size,
change their shape, modify the gene expression, and remodel the cytoskeleton and the extracellular
matrix (ECM) [12]. Importantly, during the postnatal development, hypertrophy is the prevalent way
for the heart to grow [13]. At adult age, strong exercise results in physiological hypertrophy typified
by wall and septal thickness growth (Figure 1). Stimuli of various origins, such as trophic, mechanical,
hemodynamic, and neurohumoral signals, lead to cardiac hypertrophy. In fact, the increase in cardiac
muscle mass and force produces beneficial effects aiming to normalize wall stress and preserve cardiac
output while blood filling is impaired. Pressure overload usually results in concentric hypertrophy
with relative increase in cardiomyocyte width, while volume overload typically produces eccentric
hypertrophy with increase in cardiomyocyte length, left ventricle dilatation, and heart failure (Figure 1).
Nevertheless, chronic concentric hypertrophy is the first step for the deterioration and failure of the
heart, since it leads to changes in gene expression program, contractile dysfunction, and extracellular
remodeling [14]. In fact, clinical evidence shows that hypertrophy is an important predictive factor
for adverse outcomes and increased cardiovascular mortality due to the development of heart failure,
dilated cardiomyopathy, ischaemic heart disease, and sudden death [15]. Pathological hypertrophy is
induced by different detrimental processes, such as pressure or volume overload, myocardial infarction,
hypertension, drug toxicity, and congenital heart defects. Thus, cardiac hypertrophy is a balanced
process: it is adaptive and compensatory when it is moderated and produces beneficial effects for
the heart contraction; it becomes maladaptive when it is chronic and opens the way to pathological
diseases (Figure 1). For this reason, hypertrophy could be a “good” player to be stimulated or a “bad”
mechanism to be prevented depending on the pathophysiological context.
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Figure 1. Simplified view of cardiac hypertrophy. The normal heart develops left ventricular 
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volume overload, myocardial infarction, hypertension, drug toxicity, and congenital heart defects) 
stimuli. In the physiological hypertrophy, cardiomyocytes increase in length and width. In the 
concentric hypertrophy, cardiomyocytes mostly increase in width compared with length. In the 
eccentric hypertrophy, cardiomyocytes mostly grow in length compared with width, leading to 
dilated cardiomyopathy. Except for physiological hypertrophy, hypertrophic remodeling can 
progress to contractile dysfunction and heart failure. 
3. The Role of ERK in Adaptive Cardiac Hypertrophy 
Hypertrophy is considered an adaptive process when it is coupled to an increase in the request 
of heart performance without the induction of cardiac damage. Adaptive cardiac hypertrophy 
typically occurs in healthy individuals following exercise or during pregnancy. Moreover, the 
early-induced hypertrophic response to pathological stimuli is a compensatory mechanism that is 
used by cardiomyocytes to overcome the elevated workload or injury. However, when the 
pro-hypertrophic signaling remains sustained and chronic, it becomes maladaptive and induces 
heart damage. The molecular pathways involved in the pro-hypertrophic response are often 
intertwined and play roles in both the adaptive and maladaptive hypertrophy. Physiological 
hypertrophy, such as that associated with swimming or running, is regulated in large part by the 
growth hormone/IGF axis via signaling through the PI3K/Akt pathway [16]. However, the ERK 
pathway also participates in the induction of hypertrophy in response to different external 
pathophysiological stimuli. In this section, we focus on the role exerted by ERK in adaptive 
hypertrophy. 
3.1. Adaptive Concentric Hypertrophy 
Chronic pressure overload is a pathological condition that occurs in patients with hypertension 
or stenosis of the aortic valve. At the beginning of pressure overload, the heart responds to stress by 
concentric hypertrophy. When prolonged, this compensatory process may progress to eccentric 
hypertrophy and culminates in myocardial dysfunction and heart failure. The transverse aortic 
Figure 1. Simplified view of cardiac hypertrophy. The nor al heart develops left ventricular
remodeling in response to physiological (exercise and pregnancy) and pathological (pressure or
volume overload, myocardial infarction, hypertension, drug toxicity, and congenital heart defects)
stimuli. In the physiological hypertrophy, cardiomyocytes increase in length and width. In the
concentric hypertrophy, cardiomyocytes mostly increase in width compared with length. In the
eccentric hypertrophy, cardiomyocytes mostly grow in length compared with width, leading to dilated
cardiomyopathy. Except for physiological hypertrophy, hypertrophic remodeling can progress to
contractile dysfunction and heart failure.
Mechanistically, hypertrophy is a very complex process affecting the cardiomyocyte, in which
several regulatory steps are activated in response to cardiac injury. A great number of intracellular
pathways have been associated with the hypertrophic response [14]. These pathways are intertwined,
generating a c mplex response that is still n t completely clear. Likely, they interact to regulate the
balance that defines whet er the hypertrophic process is an adaptive or maladaptive mechanism.
This concept could have a significa t implicati n for the development of therapeutic approaches to
manage the hypertrophic response and direct the process towards a more favorable outcome.
3. The Role of ERK in Adaptive Cardiac Hypertrophy
Hypertrophy is considered an adaptive process when it is coupled to an increase in the request of
heart performance without the induction of cardiac damage. Adaptive cardiac hypertrophy typically
occurs in healthy individuals following exercise or during pregnancy. Moreover, the early-induced
hypertrophic response to pathological stimuli is a compensatory mechanism that is used by
cardiomyocytes to overcome the elevated workload or injury. However, when the pro-hypertrophic
signaling remains sustained and chronic, it becomes maladaptive and induces heart damage.
The molecular pathways involved in the pro-hypertrophic response are often intertwined and play
roles in both the adaptive and maladaptive hypertrophy. Physiological hypertrophy, such as that
associated with swimming or running, is regulated i large part by the growth hormone/IGF axis via
signali g through the PI3K/Akt pathway [16]. However, the ERK pathway lso participate in the
indu tion of t in response to different external p hophysiological stimuli. In this section,
we focus on the role exerted by ERK in adaptive hypertrophy.
3.1. Adaptive Concentric Hypertrophy
Chronic pressure overload is a pathological condition that occurs in patients with hypertension
or stenosis of the aortic valve. At the beginning of pressure overload, the heart responds to stress
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by concentric hypertrophy. When prolonged, this compensatory process may progress to eccentric
hypertrophy and culminates in myocardial dysfunction and heart failure. The transverse aortic
constriction (TAC) animal model, which mimics the pressure overload human condition, was extensively
used to investigate in a spatial and temporal manner the molecular determinants involved in this
pathology [17,18]. Importantly, the TAC approach allows one to study the disease progression from
adaptive hypertrophy to heart failure, identifying the signaling pathways involved in this transition.
TAC mice showed an increase in phosphorylation of ERK in the first phase of pressure overload
stimulation, when the contractile function is maintained, whereas P-ERK was decreased at the time
of functional decompensation, when fibrosis and cardiomyocytes apoptosis appear. Thus, ERK is
stimulated during the early adaptive concentric hypertrophy and its activation is reduced during
the late detrimental eccentric hypertrophy [19]. In cardiac myocytes under pressure overload, ERK
is activated in response to G protein-coupled receptors (GPCRs) [20–24], and/or “stretch-sensitive”
sensors, such as membrane bound integrins [25], and the sarcomere itself [26]. In particular, β-arrestin,
which specifically binds GPCRs and blocks downstream G protein activation, mediates the cross-talk
of GPCRs with the RAS-RAF-MEK-ERK module (Figure 2) [20,27]. Moreover, β-arrestin facilitates
the transactivation of the epidermal growth factor receptor (EGFR) [28,29]. Transgenic mice with
cardiac-specific expression of a dominant negative form of RAF-1 (DN-RAF) were sensitized to pressure
overload pathological effects. DN-RAF mice subjected to TAC did not develop adaptive hypertrophy
and showed an increased death rate. Importantly, the cardiomyocyte apoptosis was enhanced,
indicating that the absence of RAF-1 blocks both the hypertrophic and survival signaling [30]. In line
with these results, Mutlak et al. [31] showed that the transgenic model of constitutively activated ERK
in cardiomyocytes developed adaptive hypertrophy with increased ventricular contractile function
under pressure overload. The ERK transgenic mice showed also a strong reduction in fibrosis
accumulation [31]. Accordingly, mice overexpressing DUSP6, the specific phosphatase of ERK, were
sensitized to heart failure progression when subjected to long-term TAC [32]. Overall, these scientific
reports suggest that (i) downregulation of ERK is implicated in the transition from compensated
hypertrophy to maladaptive hypertrophic heart failure during pressure overload, and that (ii) ERK is
required to prevent eccentric growth in the context of pressure overload. Indeed, stimulation of this
pathway could be a therapeutic strategy to maintain the heart performance during this pathological
hemodynamic condition.
3.2. G-Protein-Coupled Receptor (GPCR)-Induced Adaptive Hypertrophy
Stimulation of GPCRs by agonists (for example, angiotensin II (AngII) and adrenergic receptors)
recruits β-arrestin, which acts as a molecular scaffold for the RAF-MEK-ERK pathway (Figure 2).
G-protein and β-arrestin signaling pathways are not discussed here (reviewed in Reiter Lefkowitz
2013 [33]). Instead, we focus on studies involving GPCR-activated ERK signaling in cardiac
hypertrophy. GPCRs are a conserved family of transmembrane receptors that regulate a vast multitude
of physiological and pathological processes in the heart. The two main classes of GPCRs in this organ are
the adrenergic and angiotensin receptors. The adrenergic receptors enable the communication between
the sympathetic nervous and cardiovascular systems. Their role in the hypertrophic process remains
controversial. The β-adrenergic receptor (βAR) is known to be involved in the pathological induction
of heart failure. In fact, chronic activation of βAR induces apoptosis and adverse cardiac hypertrophic
remodeling [24]. On the other hand, α-adrenergic (αAR) receptors, interacting with each other and
with other adrenergic receptors, seem to positively regulate cardiac contractile and hypertrophic
responses [24]. Interestingly, data from the literature demonstrate that the α-adrenergic pathway
is involved in the development of adaptive hypertrophy during cardiac stress remodeling via the
activation of ERK signaling [34,35]. In fact, α 1A/C-AR and α 1B-AR double knockout mouse showed
a strong reduction in ERK pathway activation and a small heart with normal contractile function,
but reduced cardiac output. Importantly, the absence of α-adrenergic receptors led to an increased
mortality rate under pressure overload stimulus [34]. In addition, the loss of α1-adrenergic signaling
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induced greater pathological remodeling post-myocardial infarction (MI). In fact, α 1A-AR knockout
showed a strong shift towards pathological hypertrophy and heart failure after MI. In parallel, these
knockout mice presented reduced ERK activity and the induction of apoptosis [35]. The termination of
GPCR signaling occurs by the phosphorylation of the activated receptor and recruitment of the adapter
protein β-arrestin, a process called “desensitization.” Besides this function, β-arrestin facilitates the
activation of ERK cascade and promotes cell survival [22]. Interestingly, β-arrestin counteracts the
classical β-adrenergic-induced heart failure [28,36]. Overall, these data indicate that ERK participates
in GPCR-induced adaptive hypertrophic response against cardiac stress.
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the specificity of the MEK-ERK pathway in mammalian cells. These proteins facilitate the interaction 
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Figure 2. Schematic view of the ERK pathway in response to growth factors, hormones, and mechanical
stress. The prototypical activation of ERK cascade is initiated at the plasmamembrane by receptor
tyrosine kinases (RTKs) in response to growth factors. Activated RTKs promote RAS stimulation
through recruitment of SOS exchange factor. RAS facilitates the activation of MEK-ERK cascade
through serial phosphorylation. Once activated, ERK translocates to the nucleus and phosphorylates
transcription factors, modulating the transcription of hundreds of genes. In cardiac myocytes under
stress (aortic stenosis and hypertension), ERK is activated in response to G protein-coupled receptors
(GPCRs), and/or “stretch-sensitive” sensors, such as membrane bound integrins, and the sarcomere.
The activation of ERK cascade is regulated by scaffold proteins (KSR, Shoc2, Erbin, β-arrestin, IQGAP,
Melusin, FHL1, and ANKRD1), which bind components of the RAF-MEK-ERK module, facilitating
their functional interaction and subcellular localization. Scaffolds also link the ERK activation to specific
upstream signal and affect the duration of the signal.
3.3. Scaffold Proteins in ERK Signaling
The activation of MAPK cascade depends also on the interaction with scaffold proteins that
enable the formation of specific signaling complexes and subcellular localization (Figure 2). Originally
identified in yeast and C. elegans, scaffold proteins are now recognized to contribute to the specificity
of the MEK-ERK pathway in mammalian cells. These proteins facilitate the interaction of signaling
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components and stimulate a specific signal transduction [37]. ERK-associated scaffolding proteins
regulate the functions of the signaling module by coordinating and organizing its spatiotemporal
activation in response to different stimuli. KSR is one of the best-characterized mammalian MAPK
scaffold proteins [38]. KSR is downstream RAS and critical in recruiting the RAF-MEK-ERK complex to
the plasma membrane as well as regulating MAPK signaling strength and duration at this location [39].
However, its role in cardiac hypertrophy has yet to be investigated. Instead, other ERK-associated
scaffolding proteins have been shown to play a central role in the maintenance of cardiomyocyte
physiology and the induction of adaptive hypertrophy [40]. We have already mentioned β-arrestin as
an important scaffold for ERK activation in response to GPCRs (see above). In addition, Erbin (ErbB2
interacting protein) is able to form a complex with HER2/neu (ErbB2) and β2AR [41]. Exaggerated
pathological cardiac hypertrophy was observed in Erbin−/− mice. TAC in these mice resulted in
rapid decompensation and heart failure [42]. Recently, it has been suggested that Erbin uncouples
the Shoc2 scaffold from the RAS-RAF-MEK-ERK pathway, thus behaving as a negative regulator of
ERK signaling [43]. Moreover, the ERK-associated scaffolding protein IQGAP1 (IQ motif-containing
GTPase-activating protein 1) emerged for its function in cardiac pathophysiology. This protein has many
binding partners, which have essential roles in control of cell adhesion and actin cytoskeleton. It connects
the integrin signaling with ERK activation, by acting as a scaffold protein for the RAF-MEK-ERK
complex. IQGAP1-null mice subjected to TAC display a normal compensatory hypertrophy in the
early phase of the stimulus, but after prolonged pressure overload they show acceleration towards
the development of eccentric maladaptive hypertrophy leading to decreased heart contractility [44].
This impaired response was due to a blunted activation of the hypertrophic program and an increase
in cardiomyocyte apoptosis. Mechanistically, the lack of IQGAP1 prevents the late stimulation of ERK
signaling, which is involved in the induction of the adaptive hypertrophy, protection from apoptosis,
and the prevention of eccentric growth. Another scaffold protein organizing the ERK cascade in
cardiomyocytes and involved in the induction of cardiac compensatory hypertrophy is Melusin [45].
Melusin belongs to the family of heat shock protein 90 machinery, is specifically expressed in skeletal
and heart muscles, and binds integrin stretch-sensitive sensors. Melusin null mice did not show defects
in heart functions during physiological conditions. On the other hand, these mice failed to activate
the adaptive hypertrophic program developing impaired heart contractility in the TAC model [46].
In parallel, mice overexpressing Melusin under cardiac-specific promoter showed improved contractile
function and concentric compensatory hypertrophy when the heart was subjected to a prolonged
aortic stenosis. In addition to the adaptive hypertrophy, these mice presented reduced inflammation,
fibrosis, and apoptosis [47]. Further ERK-associated scaffolding proteins involved in the regulation of
hypertrophy are FHL1 (four and a half LIM domain protein-1) and ANKRD1 (ankyrin repeat domain 1).
These proteins are myofilament-associated proteins highly induced during the hypertrophic process in
mice and humans and are components of the sarcomere-associated biomechanical sensors. Loss of
function studies highlighted that both proteins, FHL1 and ANKRD1, have detrimental roles in Gαq
and phenylephrine-induced cardiac hypertrophy [40]. Fhl1−/− hearts displayed a blunted response to
pathological hypertrophy [48]. FHL1 directly interacts with RAF-MEK-ERK to physically insulate the
MAPK pathway to the titin N2B region of the sarcomere in a Gq stimulus-specific manner and efficiently
transmit MAPK signals to regulate cardiac hypertrophy. Ankrd1−/−mice subjected to pressure overload
via TAC were also able to maintain a normal cardiac hypertrophic response, similar to control mice [49].
In this case, ANKRD1 transmits MAPK signals to regulate the α-adrenergic associated hypertrophic
pathway [50,51]. Altogether, these findings suggest that distinct scaffolds and subcellular localization
may modulate ERK signaling in pathological states associated with cardiac hypertrophy.
3.4. Cell Death Prevention
The adaptive hypertrophic response is characterized by cell death prevention. In fact, apoptosis
is implicated as an important contributor to the pathogenesis of cardiac hypertrophy and heart
failure. As mentioned above, the ERK pathway exerts a strong anti-apoptotic function in numerous
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contexts of cardiac stress. In fact, ERK cascade promotes cardiomyocyte survival in response to pressure
overload [19,30], MI [35], and oxidative stress [52]. Mechanistically, the precise biochemical mechanisms
for the ERK-mediated anti-apoptotic effect have yet to be defined, although some associations with
the Bcl-2 family have been shown in cardiomyocytes [53,54]. In other cell types, ERK prevents
apoptosis by various mechanisms. Inhibition of Caspase 8/Bid cleavage [55] and inactivation of the
pro-apoptotic Bad [56] and Bim [57] are downstream to ERK. ERK also interferes with mitochondria
pro-apoptotic activity through the phosphorylation of caspase-9 at threonine 125 [58]. In addition
to suppressing pro-apoptotic proteins, ERK promotes anti-apoptotic molecules, among which are
Mcl-1, an anti-apoptotic member of the Bcl-2 family [59], and IEX-1, a target gene of NF-κB (nuclear
factor kappa B) that prevents the release of cytochrome c from mitochondria [60]. Whether the same
mechanisms contribute to ERK-mediated cardioprotection have yet to be identified.
4. The Role of ERK in Maladaptive Cardiac Hypertrophy
The maladaptive hypertrophy is a response to various intrinsic and extrinsic stimuli that rapidly
lead to the reduction of cardiac contractility and heart failure. In contrast to the compensatory form,
maladaptive hypertrophy is not reversible when the pathological stimulus is removed or corrected.
Often the compensatory hypertrophy, whether subjected to continuous stress, results inevitably in
decompensation and development of dilated cardiomyopathy. The detrimental hypertrophic process
characterizes different cardiovascular diseases, such as hypertension, aortic valve stenosis, or chronic
adrenergic receptor stimulation. Although the ERK pathway was identified exerting important
functions to develop the adaptive hypertrophy (see Section 3), some scientific data demonstrate
the involvement of ERK cascade in the maladaptive hypertrophy. In this section, we focus on the
ERK-mediated effects in the harmful hypertrophic process.
4.1. Hypertension
Continuous hemodynamic overload induces an unfavorable hypertrophic response. The main
pathway involved in hypertension is the renin–angiotensin system. Its main effector hormone is AngII,
which induces physiological vasoconstriction, blood pressure regulation, and production of extracellular
matrix proteins. In addition, AngII stimulates aberrant cardiac cell growth, as suggested by the high
levels of AngII after myocardial infarction and during cardiac hypertrophy [24]. The angiotensin
receptors belong to the GPCRs family, in particular the most involved in hypertension is the Gq-coupled
AT1R. Many studies support the observation that AngII induces the hypertrophic response on
myocardial cells [61]. AngII-mediated detrimental effects have a crucial role in various cardiac diseases,
such as inflammation, atherosclerosis, hypertension, and congestive heart failure. Heart failure
patients treated with inhibitors of the angiotensin system showed reduced cardiac hypertrophy and
slower progression towards heart failure [24]. These hypertrophic effects are mediated by AT1Rs,
as demonstrated by the prevention of hypertrophy through AT1R antagonists [62]. In addition,
experimental studies demonstrated increased levels of AT1R in the hypertrophic process [63]. Animal
models of AT1Rs cardiac-specific overexpression showed enhanced hypertrophy leading to heart failure,
in response to pressure overload [64]. On the other hand, the cardiac knockout of AT1Rs presented
improved systolic function with attenuation of AngII-mediated hypertrophic response in MI [65].
Importantly, ERK is activated by AT1Rs and participates in the pathological hypertrophic response [61].
In addition, it has been demonstrated that, during hypertension, ERK-induced hypertrophy can
be stimulated by mechanical stretch in an AngII-dependent or independent way [66,67]. However,
the specific mechanism by which AngII induces ERK-mediated hypertrophic process remains elusive.
Recent data show that, once activated by AT1R, P-ERK stabilized the insulin-like growth factor II
receptor (IGF-IIR) protein through the HSF1 (heat shock factor 1)/GSK3 (glycogen synthase kinase III)
pathway [68]. This suggests a feed forward mechanism involving IGF-IIR in pathological hypertrophic
response. Interestingly, mice with cardiac-specific overexpression of AT1R that are unable to couple
with G protein presented enhanced hypertrophy with decreased cell death after chronic treatment with
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AngII. Importantly, this cardioprotective hypertrophy was mediated by the ERK pathway [69]. In a way
similar to theβAR system, the AngII receptors are regulated by a “desensitization” mechanism mediated
by β-arrestin (see above). Besides its desensitization role, β-arrestin mediates the transactivation of
EGFR, stimulating ERK and thus inducing cardioprotection against AngII-mediated heart failure [36].
Thus, recruitment, activation, and scaffolding of other cytoplasmic signaling complexes may modulate
and steer ERK signaling towards adaptive or maladaptive hypertrophy.
4.2. Anthracycline-Induced Cardiotoxicity (CTX)
Anti-cancer therapy may lead to cardiac side effects with a great impact on the efficacy of treatment
and on the patient’s quality of life. Among chemotherapeutic agents, anthracyclines emerge for their
aggressive anti-tumoral activity but also for their strong detrimental effects on the heart. For this
reason, their clinical application is limited. Some scientific reports associated anthracycline-CTX to
the development of maladaptive hypertrophy, resulting in heart failure [70]. Interestingly, the ERK
pathway seems to be involved in anthracycline-CTX, but its role in this pathological context has yet to
be elucidated. A number of reports showed that ERK is stimulated by doxorubicin (doxo), likely via
mitochondrial ROS (reactive oxygen species) release [71–73]. In line with this, our own unpublished
data confirm that P-ERK is strongly induced by doxo in vitro in a dose- and time-dependent manner.
Mechanistically, ERK participates to doxo-CTX by stimulating a heat shock factor, HSF2, which
activates the AngII receptor AT1R. AT1R induction leads to cardiac cell damage and heart failure [71].
In cardiomyocytes, doxo-induced apoptosis was prevented by the pharmacological inhibition of ERK,
suggesting that ERK signaling may exert a pro-apoptotic function in the setting of doxo-CTX [72].
However, the mechanisms by which the ERK pathway induces apoptosis in cardiomyocytes need
further investigation. On the other hand, some scientific literature supports the cardioprotective
action mediated by ERK cascade against anthracycline-CTX [74,75]. Likely, ERK activation exerts both
detrimental and cardioprotective functions, and the final outcome depends on the localization, intensity,
and duration of the signal. Lou et al. suggest that ERK-mediated beneficial effects against doxo-CTX
derive from a sustained activation of ERK, since a transient and short stimulation fails to prevent heart
failure [76]. In line with this, our preliminary data show that the ERK pathway exerts an adaptive
response to anthracycline-CTX; in fact, the treatment with the ERK inhibitor sensitizes cardiomyocytes
to doxo-mediated pro-apoptotic and genotoxic effects. The combination of doxo with trastuzumab,
the humanized monoclonal antibody against the erythroblastic leukemia viral oncogene homolog
2 (ErbB2), also known as epidermal growth factor receptor-2 (HER2), demonstrated a significant
reduction in morbidity and mortality in breast cancer patients. However, severe cardiotoxic effects
emerged when trastuzumab was administered together with doxo [77]. Trastuzumab administered
alone resulted in a safe cardiac profile [78]. It is likely that the HER2-mediated pathway is required
as a cardioprotective mechanism in response to anthracycline treatment and the blockage of this
pathway exacerbates the doxo-derived CTX [79]. Indeed, HER2 signaling protects cardiomyocytes from
anthracycline-induced apoptosis and calcium/ mitochondrial dysregulation [80–82]. HER2 receptor
is known to activate the prosurvival ERK signaling in cardiomyocytes [83]. Thus, interfering with
HER2-mediated ERK signaling during or immediately after anthracycline treatment could contribute
to increase cardiomyocyte damage. Accordingly, lapatinib, a dual tyrosine kinase inhibitor targeting
the HER2 and EGFR pathways, which leads to CTX when co-administered with doxo, decreases the
activation of ERK [84]. Recently, Mohan et al. showed that trastuzumab dysregulates HER2 activity,
leading to the activation of ERK/mTOR signaling and the inhibition of autophagy in human primary
cardiomyocytes [85]. Thus, the function of ERK in the mechanism of trastuzumab-mediated CTX in
the context of doxo is complex and has yet to be completely understood.
4.3. ERK Phosphorylation at Threonine 188 (T188)
This new autophosphorylation site was discovered by Lorenz et al. in 2009 [86]. When
phosphorylated on this specific site, ERK induces maladaptive hypertrophy, as demonstrated in
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hypertrophic cardiomyocytes, animal models subjected to pressure overload, and failing human
hearts [86]. In addition, mice dominant-negative for ERK-T188 showed attenuation of pathological
hypertrophy in response to phenylephrine, an agonist for the adrenergic receptors, and chronic pressure
overload. Importantly, the lack of ERK-T188 did not produce any effect on the induction of the adaptive
hypertrophy and cell survival mediated by ERK. Moreover, phosphorylation on ERK-T188 was found
with strong prevalence in patients with a rapid progressing course of aortic valve stenosis [87]. As cited
above, the β-adrenergic receptor pathway is associated with an induction of hypertrophy leading
to failing heart [24,88]. In particular, β1AR is the subtype with a major role in the induction of
pathological hypertrophy, fibrosis, and heart failure. Notably, it has been demonstrated that β1AR
exerts its hypertrophic function by induction of ERK phosphorylation at T188. Mechanistically,
phosphorylation at T188 is produced by direct interaction between the Gs-derived Gβγ subunits of the
receptor and the activated ERK [88]. Overall, these data indicate this additional phosphorylation as a
promising pharmacological target to manage the detrimental hypertrophic process without interfering
with the adaptive ERK-mediated hypertrophy [89].
4.4. ERK5
Also known as big MAPK 1 (BMK1), ERK5 needs a separate and specific discussion. It is
characterized by a specific activating MAPKK (MEK5) and is activated by both RTKs and GPCRs [90].
ERK5 shows a different role in regulation of the hypertrophic process respect to ERK. In fact, experiments
performed in vitro in cardiomyocytes with constitutively active and dominant-negative forms of MEK5
demonstrate that ERK5 is required for elongation and serial assembly of sarcomeres. Furthermore,
MEK5 transgenic mice develop eccentric cardiac hypertrophy that leads to heart failure [10]. Scientific
data demonstrate that ERK5 is involved in the development of detrimental hypertrophy in different
pathological systems: (i) mice with cardiomyocyte-specific deletion of ERK5 showed reduction in
hypertrophic response and induction of apoptosis during pressure overload [91]; (ii) stimulation of
ERK5 was associated with eccentric and detrimental hypertrophy in an animal model of long-term
intermittent cardiac hypoxia [92]; (iii) ERK5 activation is promoted by AngII hypertrophic detrimental
stimulus [93]. In contrast, Cameron et al. found that the cardiac specific overexpression of the α
isoform of MEK5 leads to enhanced contractile function and decreased cardiomyocyte apoptosis after
ischaemic cardiac damage [94]. The reason for these discrepancies with the transgenic mice of Nicol
et al. [10] is not clear, one of the causes could be the different MEK5 isoforms used in the two studies.
In addition, Chen et al. found that, in a model of anthracycline-CTX, the induction of ERK5 by a mix of
anti-oxidant molecules plays a cardioprotective action avoiding the development of heart failure [95].
Although the role of ERK5 in heart diseases needs further investigations, the above results suggest that
it may be a potential pharmacologic target in the treatment of pathological hypertrophy associated
with different cardiac stress contexts.
5. ERK Activity in Mice Overexpressing RTKs in Cardiomyocytes
The role of ERK downstream to RTKs signaling in maladaptive cardiac hypertrophy has been
scantly studied. RTK signaling is essential for normal human cardiac function, and the genetic deletion
of RTKs can cause dilated cardiomyopathies [80,96–98]. ErbB2 conditional deletion models develop
heart failure and isolated cardiomyocytes from these mice are more sensitive to doxo [80]. ErbB2
overexpression in the heart activates protective signaling pathways (PI3K, mTOR, and Bcl-2) and
induces hypertrophy without heart failure [99]. A cardiomyocyte-specific constitutively active fibroblast
growth factor (FGF) receptor mouse model showed concentric hypertrophy with increased cardiac
mass and cardiomyocyte size, interstitial fibrosis, and myocyte disarray characteristic of hypertrophic
cardiomyopathy, without consistent ERK activation [100]. We demonstrated that the constitutive
activation of the Met proto-oncogene, the receptor for hepatocyte growth factor (HGFR), leads to the
development of concentric cardiac hypertrophy [101]. The overactivation of Met produces a strong
induction of ERK phosphorylation. Interestingly, we demonstrated that the initially formed concentric
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hypertrophy is adaptive and allows for the maintenance of the contractile force. At a later stage,
the hypertrophic remodeling converges into heart failure [101]. Importantly, the pro-hypertrophic effects
mediated by overactivated Met receptor were attenuated by the treatment with pimasertib, an MEK1
inhibitor. The attenuation of ERK signaling led to the prevention of heart failure progression [101].
On the other hand, another transgenic mouse with cardiac specific overexpression of HGF did not
develop cardiac hypertrophy, indicating negative regulatory mechanisms on ligand-activated Met
receptor signaling [102]. These data suggest that the level and the duration of the ERK pathway is
crucial to define the pro-hypertrophic response. The EGFR was also associated with hypertrophic
development in response to AngII detrimental stimulus [103,104]. Data showed that AngII induces
the ERK pathway by c-Src-mediated transactivation of EGFR. The pathological hypertrophy induced
by AngII was attenuated by the oral administration with EGFR inhibitors [104]. Finally, the ERK
cascade is involved in a norepinephrine-induced pro-hypertrophic process via stimulation of IGF1R
(insulin-like growth factor 1 receptor) [68,105,106]. Although the IGF1/PI3K/Akt pathway usually
results in physiological hypertrophy, sustained Akt stimulation may induce pathological growth.
The role of ERK in the Akt-dependent detrimental function has yet to be elucidated. Overall, these
data suggest that fine tuning of RTK signaling could be a functional therapy to treat the maladaptive
hypertrophic process.
6. ERK in Genetic Diseases with Hypertrophy
A significant percentage of cardiomyopathies have a genetic base. The genes involved in these
disorders have been increasingly discovered. Diseases with a similar phenotype are characterized
by mutations on genes encoding proteins belonging to the same pathway or with a similar structure
and function. Hypertrophy is the main feature of the hypertrophic cardiomyopathies (HCMs) and
RASopathy disorders. In this section, we elucidate the role of ERK cascade in the hypertrophic process
involved in genetic hypertrophic cardiomyopathies.
6.1. Hypertrophic Cardiomyopathies (HCMs)
HCMs are inherited diseases characterized by genetic abnormalities in contractile proteins, also
known as “disease of the sarcomere.” The majority of mutations characterizing HCMs are single
nucleotide substitutions. The mutated proteins are incorporated in the sarcomere, where they produce
non-functional contractile structure [107]. These genetic diseases are the most frequently occurring
cardiomyopathies and are the main cause of cardiac sudden death in young people. The two most
involved genes are β myosin heavy chain (βMHC), which is also the first identified mutation, and
myosin-binding protein C. The other mutated genes so far identified in HCMs are cardiac troponin
T (cTnT) and I (cTnI), myosin light chains, titin, α-tropomyosin, α-actin, α-myosin heavy chain,
and muscle LIM protein [108]. Furthermore, mutations in proteins involved in the regulation of
cardiac metabolism were found associated with HCMs: γ-2-regulatory subunit of the AMP-activated
protein kinase (PRKAG2) and the lysosome-associated membrane protein 2 (LAMP-2). In addition,
the mitochondrial myopathies due to mutations in mitochondrial DNA (including Kearns-Sayre
syndrome) or mitochondrial proteins are classified as HCM diseases [109]. Surely, many other
mutations leading to HCMs have yet to be identified. Importantly, HCMs are associated with activation
of the ERK cascade [110,111]. Guinea pig cardiomyocytes infected with adenovirus expressing
human HCM mutations in cTnT, cTnI, and α tropomyosin (αTM) showed increased myofilament
Ca2+ sensitivity—resulting in hypertrophy and contractile dysfunction—and overstimulation of
ERK [111]. ERK was also super-induced in a model of βMHC Q (403) mutation. The reduction
of ERK activity in these transgenic rabbits led to improved cardiac contractility through regression
of hypertrophy and fibrosis [110]. Recently, Davis and colleagues [112] demonstrated that ERK is
involved in the directionality of cardiac growth by mediating the addition of sarcomeres in parallel to
thicken cardiomyocytes. Isolated adult rat cardiomyocytes transduced with I61Q cardiac troponin
C (cTnC) adenovirus and subjected to 48 h of chronic pacing showed failure of ERK translocation
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to the nucleus, compared to wild-type cells. The retention of ERK in the cytosol led to increased
myocyte length, which correlated to dilated growth through cardiac cells elongation. Importantly,
double transgenic mice expressing activated MEK1 and the I61Q cTnC mutation rescued the cardiac
function and presented concentric remodeling and myocyte thickening [112]. Moreover, R193H cTnI
mutation caused a significant translocation of ERK to the nucleus, leading to reduced cardiomyocyte
length and increased width both at baseline and after chronic pacing. Co-transduction of R193H cTnI
and dominant-negative MEK1 adenoviruses blocked ERK translocation and reduced the concentric
phenotype [112]. These data indicate that mutations on sarcomeric proteins can influence the cellular
location of ERK, which determinates the type of cardiac growth in response to stressed states. Further
investigation is necessary to better elucidate the molecular mechanisms involving ERK in HCMs.
The discovery of ERK-associated scaffolding proteins linked to the sarcomeres might shed light in
these mechanisms.
6.2. RASopathies
RASopathies are human developmental genetic syndromes characterized by germline mutations
in components of the RAS-ERK cascade. The first genes identified to be mutated in RAS-related
syndromes were neurofibromin 1 and protein tyrosine phosphatase, nonreceptor type 11 (PTPN11)
(which encodes SHP2). These discoveries suggested the important roles mediated by RAS cascade in
development. The causative germline mutations are dominant gain-of-function, except for PTPN11
mutation, which is dominant-negative [8]. RASopathies are phenotypically similar diseases comprising
Noonan syndrome, Costello syndrome, Cardio-facio-cutaneous syndrome, and Leopard syndrome.
The common phenotype includes short stature, mental retardation, craniofacial dysmorphology,
and heart defects such as aortic stenosis, septal defects, and mitral insufficiency. A subset of these
syndromes often manifests cardiac hypertrophy similar to HCMs. Indeed, Costello and Leopard
syndromes show—with high frequency—hypertrophy, instead of Cardio-facio-cutaneous and Noonan
syndromes, which develop HCMs less frequently [8,113]. Importantly, experimental data suggest
the role of ERK in cardiomyocyte hypertrophy of RASopathies. In fact, muscle-specific deletion of
PTPN11 produces dilated cardiomyopathy in the absence of the hypertrophic process. The knockout
cardiomyocytes showed a strong reduction in ERK activity in response to stress stimuli, such as
pressure overload. These data suggest that PTPN11 is essential for the induction of the adaptive
hypertrophic response by regulation of ERK cascade [114]. Furthermore, the ectopically expression
of HCM-associated RAF-1 mutations from Noonan and Leopard patients showed enhancement in
ERK activity with respect to non–HCM-associated mutants [115]. Mechanistically, mutated RAF-1
protein presents reduced phosphorylation at serine 259, an inhibitory phosphorylation site, resulting
in dissociation from the scaffold protein 14-3-3 and induction in ERK activation [116]. Since KSR
interacts with 14-3-3, the involvement of ERK-associated scaffolding proteins remains to be clarified
in RASopathies. Thus, RASopathies demonstrate the importance of the signaling intensity in the
development of non-functional patterns in heart physiology. In addition, knockin mice expressing the
Noonan syndrome-associated RAF-1 (L613V) mutation showed eccentric cardiac hypertrophy and
heart failure following pressure overload. Importantly, MEK inhibition normalized the cardiac defects
in mutated mice, indicating that the enhancement in ERK activity causes HCMs and that HCMs require
a mutation-specific therapeutic approach [117]. HCMs developed in RAS-related syndromes have a
similar hypertrophic phenotype with respect to non-syndromic HCMs. Thus, the therapeutic strategies
identified for RASopathies may also be exploitable for non-syndromic HCMs.
7. Targeting ERK to Therapeutically Modulate the Cardiac Hypertrophy
Treatments targeting the hypertrophic process aim to delay or even reverse the maladaptive
remodeling. To achieve this goal, the molecular mechanism(s) and signaling pathway(s) involved in the
hypertrophic process have to be highlighted showing the similarities and differences that distinguish
pathological from physiological hypertrophy. Although ERK activation events require further dissection
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and refinements, ERK or its MAPKKs are possible therapeutic targets for a pharmacological strategy
against cardiac hypertrophic diseases. Kinase inhibitors newly developed or already in use in the
oncological field, could be exploited to mitigate excessive signaling activation in cardiac hypertrophy.
We demonstrated that pharmacological inhibition of ERK activation with Pimasertib, an orally
bio-available small-molecule inhibitor of MEK1/2, mitigates the cardiac hypertrophic phenotype of mice
expressing the constitutively activated form of Met tyrosine kinase receptor in the heart. The mitigation
and therefore the normalization of the ERK activity level were beneficial without exerting detrimental
effects [101]. In line with this, Li and colleagues showed that another drug targeting the ERK pathway,
selumetinib, could attenuate pressure overload-induced cardiac hypertrophy in vivo. Selumetinib
treatment prevented cardiomyocyte enlargement, fetal gene overexpression, and cardiac fibrosis, which
are all hallmarks of pathological hypertrophy [118]. Furthermore, ERK cascade inhibitors were tested
as potential therapeutic agents for the treatment of the RASopathies disorders. Chronic MEK-ERK
activity is critical for causing HCMs in Noonan syndrome. Indeed, Wu and colleagues showed that
postnatal MEK inhibitor treatment (PD0325901) of the knockin mouse model for syndrome-associated
RAF-1 (L613V) mutation effectively normalized cardiac anatomy and function [117]. Altogether,
these preclinical studies are encouraging towards the use of the MEK-ERK pathway inhibitors as
safe and effective cardiovascular drugs targeting cardiac hypertrophy with aberrant ERK activation.
However, considering that the cardiac hypertrophy differently affects each patient, a standard plan of
treatment cannot be designed, and an individualized therapy is required. This approach of “precision
medicine” could be important for the public health since efficacious therapeutic strategies directly
interfering with the hypertrophy development are still lacking. In fact, the management of symptomatic
cardiac hypertrophy is based on medications relieving symptoms or, at worst, surgical procedures.
However, a word of caution is warranted regarding the use and development of ERK-targeted
therapies, as the ERK cascade is well known to exert cytoprotective functions. In particular, the total
blockage of ERK cascade during cardiac stress, such as pressure overload, MI, and oxidative stress,
could produce important irreversible cardiac damage. The development of new selective inhibitors
leaving the ERK antiapoptotic effects intact may pave the way in future to impairment of ERK-driven
pathological hypertrophy.
8. Conclusions
Cardiac hypertrophy is a complex response to various physiological and pathological stimuli.
Adaptive concentric hypertrophy is a compensatory process that counteracts the hemodynamic
overload. When the pathological stimulus is sustained and chronic, hypertrophy becomes eccentric
and maladaptive, leading to heart failure. There is no doubt that the ERK cascade is a key player in the
hypertrophic process. Activation of the ERK pathway is involved in both adaptive and maladaptive
hypertrophy, depending on the pathophysiological context (Table 1).
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Table 1. Modulation of ERK signaling by extrinsic and intrinsic stimuli.
Extrinsic Stimuli
Experimental Models Response References
Pressure Overload Transverse aortic constriction (TAC) in mice Early adaptive concentric hypertrophy; ERK ↑;
Late detrimental eccentric hypertrophy; ERK ↓
[19]
Aortic Valve Stenosis Human patients Detrimental eccentric hypertrophy; ERK ↓ [87]
AngII Cardiomyocytes ERK5 ↑; ERK ↑ [10,93,104]
AngII inhibitors Heart failure patients Reduction of cardiac hypertrophy and heart failure; ERK ↓ [24]
Isopreteronol βAR stimulation in mice Cardiac hypertrophy and fibrosis; ERK phosphorylation at T188 ↑ [88]
βAR Blockers In vitro treatment Arrestin-mediated EGF receptor transactivation; ERK ↑ [28,29]
Anthracycline In vitro and in vivo treatments Heart failure; ERK ↑ [71,72]
In vitro and in vivo treatments Cardioprotective action; ERK ↑ [74–76]
Rat cardiomyocytes
(Lapatinib and Doxorubicin)
Cardiotoxicity; ERK ↓ [84]
Trastuzumab Human cardiomyocytes Cardiotoxicity; ERK ↑ [85]
Intrinsic Stimuli
Experimental Models Response References
DN RAF-1 Cardiomyocytes-specific Tg mice Blunted response to pathological hypertrophy; ERK ↓ [30]
DUSP-6 Cardiomyocytes-specific Tg mice Heart failure in response to TAC; ERK ↓ [32]
MEK1 Cardiomyocytes-specific Tg mice Concentric cardiac hypertrophy; ERK ↑ [4]
MEK5β Cardiomyocytes-specific Tg mice Eccentric cardiac hypertrophy and heart failure; ERK5 ↑ [10]
MEK5α Cardiomyocytes-specific Tg mice Prevention of heart failure in response to MI; ERK5 ↑ [94]
ERK5 Cardiomyocytes-specific knock out mice Reduced cardiac hypertrophy, and increased apoptosis in response to TAC; ERK5 ↓ [91]
αAR α(1A/C)AR and α(1B)AR double knock out mice Small heart with reduced cardiac output in response to TAC; ERK ↓ [34]
α1AR knock out mice Pathological hypertrophy and heart failure in response to MI; ERK ↓ [35]
β1AR Cardiomyocytes-specific Tg mutant mice Lack of EGFR transactivation; Increased contractility, fibrosis and apoptosis; ERK ↓ [28]
βArrestin In vitro knock out Arrestin 1: ERK ↑; Arrestin 2: ERK ↓ [21]
βArrestin Knock out mice Lack of EGFR transactivation; ERK ↓ [28,29]
Erbin Knock out mice Cardiac hypertrophy and heart failure in response to TAC; ERK ↓ [42]
IQGAP1 Knock out mice Eccentric hypertrophy in response to TAC; ERK ↓ [44]
Melusin Cardiomyocytes-specific Tg mice Concentric hypertrophy, improved response to TAC; ERK ↑ [47]
FHL1 Knock out mice Blunted response to pathological hypertrophy; ERK ↓ [48]
ANKRD1 Cardiomyocytes knock down and knock out mice Blunted response to pathological hypertrophy; ERK ↓ [51]
ERK2 T188A Cardiomyocytes-specific Tg mice Attenuation of pathological hypertrophy in response to GPCRs activation and TAC [87,88]
HGFR Cardiomyocytes-specific Tg mice Early adaptive concentric hypertrophy; late heart failure; ERK ↑ [101]
EGFR In vitro and in vivo protein knock down Failure of AngII-mediated cardiac hypertrophy; ERK ↓ [103,104]
IGF1R Cardiomyocytes-specific protein knock down in mice Attenuation of norepinephrine-induced cardiac hypertrophy; ERK ↓ [105]
HCM βMHC-Q(403) in Tg rabbits Cardiac hypertrophy, fibrosis, and contractile dysfunction; ERK ↑ [110]
cTnT R92Q, cTnI R145G, and αTM D175N in cardiomyocytes Cardiomyocyte hypertrophy; ERK ↑ [111]
I61Q cTnC in cardiomyocytes Failure of ERK translocation to the nucleus and cardiomyocytes elongation [112]
R193H cTnI in cardiomyocytes ERK translocation to the nucleus and increased cardiomyocytes width [112]
RASopathies Cardiomyocytes-specific knock out of PTPN11 in mice Failure in the induction of adaptive hypertrophy; ERK ↓ [114]
Noonan RAF-1 L613V mutation knock in mice Eccentric hypertrophy and heart failure; ERK ↑ [117]
↑ increased or ↓ decreased levels of phosphorylation at regulatory TEY site.
Int. J. Mol. Sci. 2019, 20, 2164 14 of 21
However, some issues remain controversial and need to be elucidated. In particular, ERK seems
to exert beneficial hypertrophic effects during chronic pressure overload, through cell death prevention
and regulation of hypertrophy. On the other hand, ERK participates in detrimental hypertrophy during
hypertension and cardiac side effects mediated by chemotherapy. It appears that not all ERK activation
events are the same. Duration, intensity, frequency, and cytoplasmic versus nuclear localization of
activated ERK may influence the final outcome. β-arrestin recruitment to GPCRs induces selective
coupling to ERK beneficial activation. ERK-associated scaffold proteins are critical determinants for the
spatial specificity of the signal. IQGAP1 and Melusin are involved in the adaptive pro-hypertrophic
process, conversely FHL1 and ANKRD1 are associated with maladaptive hypertrophy. In addition,
ERK phosphorylated at threonine 188 and ERK5 isoform are associated with pathological hypertrophy.
ERK activation is found in the hypertrophic cardiomyopathy of sarcomere genetic diseases and in
RASopathies. These findings strengthen the view that ERK is important for hypertrophy. Overall,
these data suggest that both the activation and the inhibition of the ERK cascade could be targeted for
therapy in cardiac hypertrophy. Given the importance of the RAS-RAF-MEK-ERK pathway in cancer,
novel pharmacological ERK inhibitors will be available in the near future that could be of interest for
their clinical applicability in cardiac disease. In parallel, the use of ERK-targeted therapies in cancer
must be deeply evaluated to avoid unwanted side effects in the heart.
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ANKRD1 ankyrin repeat domain 1
βAR β-adrenergic receptor
βMHC β myosin heavy chain
BMK1 big MAPK 1
CTX cardiotoxicity
cTnC cardiac troponin C
cTnI cardiac troponin I
cTnT cardiac troponin T
Doxo doxorubicin
ECM extracellular matrix
EGFR epidermal growth factor receptor
ErbB2 erythroblastic leukemia viral oncogene homolog 2
ERK extracellular signal-regulated kinase
FGF fibroblast growth factor
FHL1 four and a half LIM domain protein-1
GPCR G-protein-coupled receptor
GSK3 glycogen synthase kinase III
HCM hypertrophic cardiomyopathy
HER2 epidermal growth factor receptor 2
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HGFR hepatocyte growth factor receptor
HSF heat shock factor
IGFR insulin-like growth factor receptor
IQGAP1 IQ motif-containing GTPase-activating protein 1
LAMP-2 lysosome-associated membrane protein 2
MAPK mitogen-activated protein kinase
MI myocardial infarction
NF-κB nuclear factor kappa B
PRKAG2 γ-2-regulatory subunit of the AMP-activated protein kinase
PTPN11 protein tyrosine phosphatase, nonreceptor type 11
ROS reactive oxygen species
RTK receptor tyrosine kinase
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